Report #2848923

Overview

Sex

Female

Age

Age unknown

State

NC

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

3rd dose received after 6 months (longer than recommended); 2nd dose received on 21st days; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On an unknown date, the patient received the 3rd dose of Twinrix and the 2nd dose of Twinrix. On an unknown date, an unknown time after receiving Twinrix and not applicable after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: 3rd dose received after 6 months (longer than recommended)) and drug dose administration interval too short (Verbatim: 2nd dose received on 21st days). The outcome of the drug dose administration interval too long and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 27-JUN-2025 The reporter was a female adult patient. The patient was also a HCP (Pharmacist). The patient received Twinrix in 2013 or 2014. The patient received Twinrix at 0 month, 21 days, and 6-month schedule. The patient received 3rd dose of Twinrix,?later than the recommended interval, which led to lengthening of vaccinations schedule. The patient received 2nd dose of Twinrix,?earlier than the recommended interval, which led to shortening of vaccinations schedule. This case is linked with US2025081319 reported by same reporter.; Sender's Comments: US-GSK-US2025081319:Same reporter,Different patient

Other medications

TWINRIX